Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study ; volume:22 ; number:1 ; day:28 ; month:5 ; year:2022 ; pages:1-16 ; date:12.2022
BMC psychiatry ; 22, Heft 1 (28.5.2022), 1-16, 12.2022
- Creator
-
Llorca, Pierre-Michel
Nuss, Philippe
Fakra, Éric
Alamome, Isabelle
Drapier, Dominique
El Hage, Wissam
Jardri, Renaud
Mouchabac, Stéphane
Rabbani, Marc
Simon, Nicolas
Vacheron, Marie-Noëlle
Azorin, Jean-Michel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-022-04008-9
- URN
-
urn:nbn:de:101:1-2022081621490395587072
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Llorca, Pierre-Michel
- Nuss, Philippe
- Fakra, Éric
- Alamome, Isabelle
- Drapier, Dominique
- El Hage, Wissam
- Jardri, Renaud
- Mouchabac, Stéphane
- Rabbani, Marc
- Simon, Nicolas
- Vacheron, Marie-Noëlle
- Azorin, Jean-Michel
- SpringerLink (Online service)
Other Objects (12)
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study